These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33205203)

  • 1. Concurrent Infection With Multiple Human Papillomavirus Types Among Unvaccinated and Vaccinated 17-Year-Old Norwegian Girls.
    Laake I; Feiring B; Jonassen CM; Pettersson JHO; Frengen TG; Kirkeleite IØ; Trogstad L
    J Infect Dis; 2022 Sep; 226(4):625-633. PubMed ID: 33205203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.
    Feiring B; Laake I; Christiansen IK; Hansen M; Stålcrantz J; Ambur OH; Magnus P; Jonassen CM; Trogstad L
    J Infect Dis; 2018 Nov; 218(12):1900-1910. PubMed ID: 30010913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
    Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
    PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.
    Donkoh ET; Dassah ET; Owusu-Dabo E
    BMC Womens Health; 2022 Jun; 22(1):234. PubMed ID: 35710373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
    Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
    Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Papillomavirus Antibody Levels Following Vaccination or Natural Infection Among Young Men Who Have Sex With Men.
    Chow EPF; Fairley CK; Zou H; Wigan R; Garland SM; Cornall AM; Atchison S; Tabrizi SN; Chen MY
    Clin Infect Dis; 2022 Aug; 75(2):323-329. PubMed ID: 34971362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
    Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
    Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination.
    Batmunkh T; Dalmau MT; Munkhsaikhan ME; Khorolsuren T; Namjil N; Surenjav U; Toh ZQ; Licciardi PV; Russell FM; Garland SM; Mulholland K; von Mollendorf C
    Vaccine; 2020 Jun; 38(27):4316-4324. PubMed ID: 32387009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partner-Level and Sexual Networking Factors Are Associated With Vaccine-Type and Nonvaccine-Type Human Papillomavirus Infection After Vaccine Introduction in Young Women.
    Kahn J; Washington C; Ding L; Wyllie T; Rosen B; Gorbach P
    Sex Transm Dis; 2022 Jun; 49(6):429-436. PubMed ID: 35093984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
    Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
    Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
    Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline prevalence and type distribution of Human papillomavirus in sexually active non-vaccinated adolescent girls from Argentina.
    González JV; Deluca GD; Liotta DJ; Correa RM; Basiletti JA; Colucci MC; Katz N; Vizzotti C; Picconi MA; ;
    Rev Argent Microbiol; 2021; 53(1):11-19. PubMed ID: 32788072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
    Kavanagh K; Pollock KG; Cuschieri K; Palmer T; Cameron RL; Watt C; Bhatia R; Moore C; Cubie H; Cruickshank M; Robertson C
    Lancet Infect Dis; 2017 Dec; 17(12):1293-1302. PubMed ID: 28965955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
    Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
    Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
    Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
    Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II).
    Gray P; Palmroth J; Luostarinen T; Apter D; Dubin G; Garnett G; Eriksson T; Natunen K; Merikukka M; Pimenoff V; Söderlund-Strand A; Vänskä S; Paavonen J; Pukkala E; Dillner J; Lehtinen M
    Int J Cancer; 2018 Jun; 142(12):2491-2500. PubMed ID: 29377141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of multiple human papillomavirus infection and type competition: An analysis in healthy Chinese women aged 18-45 years.
    Su Y; Zheng T; Bi Z; Jia X; Li Y; Kuang X; Yang Y; Chen Q; Lin H; Huang Y; Huang S; Qiao Y; Wu T; Zhang J; Xia N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2334474. PubMed ID: 38619081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine Hesitancy Drives Low Human Papillomavirus Vaccination Coverage in Girls Attending Public Schools in South Africa.
    Khosa LA; Meyer JC; Motshwane FMM; Dochez C; Burnett RJ
    Front Public Health; 2022; 10():860809. PubMed ID: 35685759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
    Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
    BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.